Carlsmed Raises $52.5M in Series C Financing for Advancing Personalized Spine Surgery

Carlsmed, an AI-enabled personalized surgery Medtech company announced a $52.5M Series C funding round co-led by U.S. Venture Partners and B Capital. Proceeds will be used to advance the commercialization of its aprevo personalized spine surgery platform for lumbar fusion procedures and developing aprevo for cervical fusions that will launch in 2025. 
 
“We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo patient-specific implants are achieving this goal,” the CEO of Carlsmed, Mike Cordonnier commented. “Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”
 
The company received Breakthrough Device designation from the FDA for aprevo lumbar and cervical patient-specific interbody fusion devices. Carlsmed implantable devices and software platforms are FDA-cleared for lumbar spine fusion including lateral, anterior, and transforaminal approaches.
 
General Partner and Head of Healthcare at B Capital, Dr. Robert Mittendorff, said, “Carlsmed is transforming spine surgery through the application of its AI-enabled technology and has proven to be a category creator in a market overdue for meaningful innovation. Personalized surgery will be the standard of care in spine, and we look forward to supporting this transformation led by Carlsmed.”